3月5日,CDE 官网显示,翰森制药阿美替尼新适应症申报上市。此次阿美替尼适应症为:联合达麦利替尼用于治疗表皮生长因子受体(EGFR)基因突变阳性、经 EGFR 酪氨酸激酶抑制剂(TKI)治疗后疾病进展、且伴有间质-上皮转化因子(MET)扩增的局部晚期或转移性非小细胞肺癌(NSCLC)患者。阿美替尼是翰森制药自主研发的拳头产品,也是国内首个获批的三代EGFR-TKI。这款药物在结构上引入了环丙基,...
Source Link3月5日,CDE 官网显示,翰森制药阿美替尼新适应症申报上市。此次阿美替尼适应症为:联合达麦利替尼用于治疗表皮生长因子受体(EGFR)基因突变阳性、经 EGFR 酪氨酸激酶抑制剂(TKI)治疗后疾病进展、且伴有间质-上皮转化因子(MET)扩增的局部晚期或转移性非小细胞肺癌(NSCLC)患者。阿美替尼是翰森制药自主研发的拳头产品,也是国内首个获批的三代EGFR-TKI。这款药物在结构上引入了环丙基,...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.